Letter

Dornase alfa for cystic fibrosis

BMJ 1995; 311 doi: 10.1136/bmj.311.7008.813 (Published 23 September 1995)
Cite this as: BMJ 1995;311:813.1

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Glenn Robert,
  2. Andrew Stevens,
  3. Duncan Colin-Jones
  1. Research assistant Senior lecturer in public health medicine Wessex Institute of Public Health Medicine, Winchester SO22 5DH
  2. Chairman, development and evaluation committee Queen Alexandra Hospital, Cosham, Portsmouth PO6 3LY

    EDITOR,--The use of dornase alfa has been a topic of recent controversy.1 2 3 South and West region's development and evaluation committee of senior clinicians supported by a research review team undertook to determine the drug's cost effectiveness on the basis of the published evidence.4 The net cost (total costs less savings) to the NHS of prescribing a daily dose of 2.5 mg of dornase alfa to patients with cystic fibrosis in the former Wessex Regional Health Authority, excluding children under …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    Read related article

    See previous polls

    BMJ most popular